A phase I trial of ipilimumab plus bevacizumab in patients with unresectable stage III or stage IV melanoma

被引：13
|
作者：
Hodi, F. S.
Friedlander, P. A.
Atkins, M. B.
McDermott, D. F.
Lawrence, D. P.
Ibrahim, N.
Wu, X.
Zhou, J.
Giobbie-Hurder, A.
Murphy, G.
Hollman, T.
Velazquez, E.
Russell, S.
Dipiro, P.
Yap, J. T.
Van den Abbeele, A. D.
机构：
[1] Dana Farber Canc Inst, Boston, MA 02115 USA
[2] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA
[3] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA
[4] IBCSG Stat Ctr, Boston, MA USA
[5] Brigham & Womens Hosp, Boston, MA 02115 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 15期
关键词：
D O I：
10.1200/jco.2011.29.15_suppl.8511
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8511
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Phase II study of ipilimumab in adolescents with unresectable stage III or IV malignant melanoma
    Geoerger, Birgit
    Bergeron, Christophe
    Gore, Lia
    Sender, Leonard
    Dunkel, Ira J.
    Herzog, Cynthia
    Brochez, Lieve
    Cruz, Ofelia
    Nysom, Karsten
    Berghorn, Elmer
    Simsek, Burcin
    Shen, Jun
    Pappo, Alberto
    EUROPEAN JOURNAL OF CANCER, 2017, 86 : 358 - 363
  • [2] Ipilimumab (MDX-010) in patients with unresectable stage III or IV malignant melanoma: efficacy and safety data from a phase I trial
    Weber, J.
    Hersh, E.
    Yellin, M.
    Nichol, G.
    Urba, W.
    Powderly, J.
    O'Day, S.
    EJC SUPPLEMENTS, 2007, 5 (04): : 396 - 396
  • [3] The efficacy and safety of ipilimumab (MDX-010) in patients with unresectable stage III or stage IV malignant melanoma
    Weber, J. S.
    Hersh, E. M.
    Yellin, M.
    Nichol, G. M.
    Urba, W.
    Powderly, J. D.
    O'Day, S. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [4] Phase II trial of carboplatin, weekly paclitaxel, and biweekly bevacizumab in patients with unresectable stage IV melanoma
    Perez, D. G.
    Suman, V.
    Amatruda, T.
    Gornet, M.
    Morton, R.
    Jilani, S.
    Constantinou, C.
    Egner, J.
    Markovic, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [5] Peripheral and local predictive immune signatures identified in a phase II trial of ipilimumab with carboplatin/paclitaxel in unresectable stage III or stage IV melanoma
    Jamal, Rahima
    Lapointe, Rejean
    Cocolakis, Eftihia
    Thebault, Pamela
    Kazemi, Shirin
    Friedmann, Jennifer E.
    Dionne, Jeanne
    Cailhier, Jean-Francois
    Belanger, Karl
    Ayoub, Jean-Pierre
    Le, Huy
    Lambert, Caroline
    El-Hajjar, Jida
    van Kempen, Leon C.
    Spatz, Alan
    Miller, Wilson H., Jr.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2017, 5
  • [6] A phase I study of intratumoral injection of ipilimumab and interleukin-2 in patients with unresectable stage III-IV melanoma.
    Bowen, Randy Christopher
    Meek, Stephanie
    Williams, Matthew
    Grossmann, Kenneth F.
    Andtbacka, Robert Hans Ingemar
    Bowles, Tawnya Lynn
    Hyngstrom, John Robert
    Leachman, Sancy Ann
    Grossman, Douglas
    Holmen, Sheri L.
    VanBrocklin, Matthew W.
    Khong, Hung T.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [7] Ipilimumab for stage unresectable III/IV melanoma: Brazilian experience in an expanded access program
    Schmerling, Rafael
    Herchenhorn, Daniel
    Rinck, Jose Augusto
    De Camargo, Veridiana Pires
    Camargo, Johnny
    Serrano, Sergio Vicente
    Azevedo, Sergio Jobim
    Barrios, Carlos H.
    Martina Segalia, Jose Getulio
    Bertoni, Vanessa Dybal
    Buzald, Antonio C.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [8] The cost of unresectable stage III or stage IV melanoma in Italy
    Maio, Michele
    Ascierto, Paolo
    Testori, Alessandro
    Ridolfi, Ruggero
    Bajetta, Emilio
    Queirolo, Paola
    Guida, Michele
    Romanini, Antonella
    Chiarion-Sileni, Vanna
    Pigozzo, Jacopo
    Di Giacomo, Anna Maria
    Calandriello, Mario
    Didoni, Guido
    van Baardewijk, Marck
    Konto, Cyril
    Lucioni, Carlo
    JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2012, 31
  • [9] The cost of unresectable stage III or stage IV melanoma in Italy
    Michele Maio
    Paolo Ascierto
    Alessandro Testori
    Ruggero Ridolfi
    Emilio Bajetta
    Paola Queirolo
    Michele Guida
    Antonella Romanini
    Vanna Chiarion-Sileni
    Jacopo Pigozzo
    Anna Maria Di Giacomo
    Mario Calandriello
    Guido Didoni
    Marck van Baardewijk
    Cyril Konto
    Carlo Lucioni
    Journal of Experimental & Clinical Cancer Research, 31
  • [10] CHARLI: A phase Ib/II trial of ipilimumab-nivolumab-denosumab or nivolumab-denosumab in patients with unresectable stage III and IV melanoma.
    Lau, Peter Kar Han
    Harris, Samuel John
    Eastgate, Melissa A.
    Kee, Damien
    Mant, Andrew
    Nott, Louise M.
    Gedye, Craig
    Inderjeeth, Andrisha Jade
    Underhill, Craig
    Weppler, Alison Margaret
    Wallace, Roslyn
    Lee, Belinda
    Au-Yeung, George
    Williams, Narelle
    Ospino, Daniel Ariza
    Gonzales, Louise
    Shackleton, Mark J.
    Lo, Serigne N.
    McArthur, Grant A.
    Sandhu, Shahneen
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
12345